Eun A. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eun A. Lee has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Kyungjae Myung
Center for Genomic Integrity, Institute for Basic Science, Ulsan 44919, Republic of Korea
22 shared publications - Chang Sik Yu
Division of Colon and Rectal Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
20 shared publications - Dayoung Kim
Ulsan National Institute of Science and Technology, Korea (South), Republic of
20 shared publications - Deok-Beom Jung
Asan Medical Center, Seoul, Korea (South), Republic of
20 shared publications - Euihwan Jeong
Cascure Therapeutics, Korea (South), Republic of
20 shared publications - Eunjin Lee
Ulsan National Institute of Science and Technology, Ulsan, N/A, Korea (South), Republic of
20 shared publications
Latest Publications
- Open Access
- 4 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Targeting IP6 signaling to destabilize homologous recombination proteins to overcome PARP inhibitor resistance
Homologous recombination (HR) is crucial for maintaining genomic integrity and is tightly regulated, yet the role of ubiquitin-dependent degradation in HR proteins remains poorly understood. Through high-throughput screening for compounds that modulate the DNA replication stress response, we identify ML367 and its derivative, UNI418. Kinase profiling and detail molecular analyses reveal that UNI418 inhibits PIKfyve and PIP5K1C, reducing inositol hexaphosphate (IP6) levels and triggering Cul4A-dependent degradation of RAD51, CtIP, and CHK1. Further analysis identifies WDR5 as a DCAF protein that facilitates Cul4A-mediated proteolysis of RAD51 and CHK1. Functionally, UNI418 suppresses HR, enhances tumor sensitivity to PARP inhibitors (PARPis), and re-sensitizes PARPi-resistant tumor cells in both in vitro and in vivo xenograft models. These findings reveal a Cul4A-WDR5-dependent proteolysis pathway regulating HR protein stability via phosphatidyl inositol signaling. This mechanism offers a promising therapeutic strategy for overcoming PARPi resistance and improving combinatorial cancer treatment strategies.
- 4 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTargeting IP6 signaling to destabilize homologous recombination proteins to overcome PARP inhibitor resistance
Homologous recombination (HR) is crucial for maintaining genomic integrity and is tightly regulated, yet the role of ubiquitin-dependent degradation in HR proteins remains poorly understood. Through high-throughput screening for compounds that modulate the DNA replication stress response, we identify ML367 and its derivative, UNI418. Kinase profiling and detail molecular analyses reveal that UNI418 inhibits PIKfyve and PIP5K1C, reducing inositol hexaphosphate (IP6) levels and triggering Cul4A-dependent degradation of RAD51, CtIP, and CHK1. Further analysis identifies WDR5 as a DCAF protein that facilitates Cul4A-mediated proteolysis of RAD51 and CHK1. Functionally, UNI418 suppresses HR, enhances tumor sensitivity to PARP inhibitors (PARPis), and re-sensitizes PARPi-resistant tumor cells in both in vitro and in vivo xenograft models. These findings reveal a Cul4A-WDR5-dependent proteolysis pathway regulating HR protein stability via phosphatidyl inositol signaling. This mechanism offers a promising therapeutic strategy for overcoming PARPi resistance and improving combinatorial cancer treatment strategies.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Table S4 provides information on the putative off-target sites of each sgRNA in Hmix-4, as identified by Cas-Offinder and CRISPOR analyses.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Table S4 provides information on the putative off-target sites of each sgRNA in Hmix-4, as identified by Cas-Offinder and CRISPOR analyses.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S14 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S14 shows quantitative measurements of BRCA2 expression upon siRNA or shRNA-mediated knock-down, and verifies the synthetic lethality of PARP inhibition in BRCA2-deficient cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S14 shows quantitative measurements of BRCA2 expression upon siRNA or shRNA-mediated knock-down, and verifies the synthetic lethality of PARP inhibition in BRCA2-deficient cells.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S4 evaluates the specificity and safety of multiplexed CRISPR-induced cytotoxicity by examining its effects on non-target loci and various cell lines.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S4 evaluates the specificity and safety of multiplexed CRISPR-induced cytotoxicity by examining its effects on non-target loci and various cell lines.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S10 evaluates the in vivo antitumor effects of sgRNA-loaded liposomes in a mouse xenograft model using HCT-116 cells stably expressing Cas9 nucleases.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S10 evaluates the in vivo antitumor effects of sgRNA-loaded liposomes in a mouse xenograft model using HCT-116 cells stably expressing Cas9 nucleases.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S6 illustrates how predicted SpCas9 activity and CRISPR-induced mutation patterns affect the efficiency of cell death following multiplexed CRISPR targeting.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S6 illustrates how predicted SpCas9 activity and CRISPR-induced mutation patterns affect the efficiency of cell death following multiplexed CRISPR targeting.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S13 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S13 demonstrates the inhibitory role of olaparib in the repair of DNA single-strand breaks induced by multiplexed CRISPR/nCas9D10A.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S13 demonstrates the inhibitory role of olaparib in the repair of DNA single-strand breaks induced by multiplexed CRISPR/nCas9D10A.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S2 presents representative images demonstrating the effect of RNP- or RNA-based delivery of multiplexed CRISPR/Cas systems on cell viability in various cancer cell lines.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S2 presents representative images demonstrating the effect of RNP- or RNA-based delivery of multiplexed CRISPR/Cas systems on cell viability in various cancer cell lines.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S9 provides high-resolution whole-slide immunohistochemical images of HCT-116 xenograft tumors treated with either PBS or multiplexed CRISPR/Cas9WT RNP-loaded LNPs.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S9 provides high-resolution whole-slide immunohistochemical images of HCT-116 xenograft tumors treated with either PBS or multiplexed CRISPR/Cas9WT RNP-loaded LNPs.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S7 presents bright-field images showing that multiplexed sgRNAs targeting proximal sites near the C4BPB gene do not induce cytotoxic effects.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Combining Multiplexed CRISPR/Cas9-Nickase and PARP Inhibitors Efficiently and Precisely Targets Cancer Cells
Figure S7 presents bright-field images showing that multiplexed sgRNAs targeting proximal sites near the C4BPB gene do not induce cytotoxic effects.